"Product Profiles: Autism Spectrum Disorders - Growing interest in underserved market" Published
Over the past 6 years, three major events have impacted the autism spectrum disorders market. In 2006, Risperdal became the first drug to receive approval from the US FDA for the symptomatic treatment of irritability in children and adolescents with ASDs. Later, in 2009, the FDA approved Abilify for the same indication. In 2008, generic risperidone launched following Risperdal's US patent expiry.
View full press release